Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet Holdings, Inc. has appointed Vafa Jamali as the CEO of NewCo, a spin-off company which will focus on the Spine and Dental sectors, expected to launch in mid-2022. Jamali brings over 25 years of medical device experience, previously holding leadership roles at Rockley Photonics and Medtronic, where he led a $3 billion revenue division. His expertise is anticipated to drive growth and investment strategies for NewCo. Bryan Hanson, the current CEO of Zimmer Biomet, expressed confidence in Jamali’s ability to lead the new venture successfully.
Zimmer Biomet (ZBH) announced that President and CEO Bryan Hanson, along with Executive Vice President and CFO Suky Upadhyay, will present at Citi's 2021 Healthcare Services Conference on February 24, 2021, at 10:45 a.m. ET. A live webcast can be accessed via their Investor Relations website, which will also archive the presentation for later viewing. Zimmer Biomet, headquartered in Warsaw, Indiana, is a key player in musculoskeletal healthcare, offering a wide range of medical products and solutions.
Zimmer Biomet (NYSE: ZBH) plans to spin off its Spine and Dental businesses into a new independent company, NewCo, aiming to optimize growth and stakeholder value. This strategic move, part of Zimmer Biomet's transformation, focuses resources on higher-growth markets, including orthopedics and dental sectors. The spin-off, expected mid-2022, is designed to create stronger growth profiles for both companies while achieving a more targeted investment opportunity. The 2019 and 2020 pro forma revenue for Zimmer Biomet was $6.96 billion and $6.128 billion, respectively.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported its Q4 2020 results, revealing net sales of $2.085 billion, down 1.9%, with full-year sales at $7.025 billion, a 12% decrease. Q4 net earnings reached $333.7 million, equating to diluted EPS of $1.59, a 3.2% increase year-over-year. Adjusted diluted EPS fell 8.3% to $2.11. The company announced plans to spin off its Spine and Dental divisions to enhance focus and growth. Despite strong operational performance, the ongoing impact of COVID-19 on elective procedures continues to hinder recovery.
Zimmer Biomet Holdings has appointed Ellison M. Humphrey as the Chief Transformation Officer, reporting directly to Bryan C. Hanson, President and CEO. Humphrey joins from Medtronic, where she held leadership roles including Vice President of Enterprise Excellence. In her new role, she will connect key initiatives to drive an integrated transformation strategy across the organization. Her extensive experience, including a background at McKinsey & Company and degrees from Harvard and the University of Virginia, is expected to advance Zimmer Biomet’s goals within the evolving healthcare landscape.
Zimmer Biomet Holdings (ZBH) will host a fourth quarter earnings conference call on February 5, 2021, at 8:30 a.m. ET, following a news release of financial results at 6:30 a.m. ET the same day. The conference call will be accessible via their Investor Relations website and will be archived for replay. U.S. and Canadian participants can join by calling (888) 312-9837 using conference ID 7278985. The digital recording will be available until April 6, 2021.
Zimmer Biomet Holdings (ZBH) has announced a $0.24 quarterly cash dividend for Q4 2020. This dividend will be paid on or about January 29, 2021 to stockholders on record as of the close of business on December 28, 2020. Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, providing various orthopedic products worldwide.
Zimmer Biomet Holdings (NYSE: ZBH) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 p.m. ET. Presenters include President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. A live webcast will be available on Zimmer Biomet's Investor Relations website and archived for future viewing. Zimmer Biomet is a leader in musculoskeletal healthcare, designing and marketing a wide range of orthopedic and surgical products globally.
Zimmer Biomet Holdings and Hospital for Special Surgery (HSS) have announced an exclusive agreement to implement HSS Orthopedic Care Pathways via the mymobility platform with Apple Watch. This collaboration aims to enhance remote patient care through state-of-the-art surgical care protocols. By utilizing Apple Watch's sensors, physicians can monitor patients' activity and recovery metrics, facilitating virtual doctor-patient interactions and potentially lowering care costs. The new pathways will be available globally in early 2021.
Zimmer Biomet Holdings (NYSE: ZBH) has launched the Zimmer Biomet Foundation, a philanthropic organization aimed at supporting diverse and underserved communities. The Foundation will focus on STEM education, community health, and disaster relief. Zimmer Biomet pledges $2 million over three years in partnership with the NAACP to combat racial injustice and promote diversity. This initiative is part of a larger commitment of at least $5 million over five years towards anti-racism and diversity efforts. The Foundation will also match employee contributions to non-profits.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
